Silence Therapeutics (SLN) said Monday that Chief Executive and President Craig Tooman "agreed by mutual consent" to terminate his employment with the company, effective Dec. 14.
Board Chair Iain Ross will lead Silence on an interim basis, effective immediately, the company said.
Silence shares were down 2% in early trading Monday.
Price: 6.20, Change: -0.13, Percent Change: -1.98